| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Tris(pentafluorophenyl)phosphine does not have a defined biological target as a therapeutic agent. It is an organophosphorus compound used as a ligand in organometallic chemistry and catalysis. The compound is not intended to exert pharmacological effects. Its utility lies in its chemical properties as a ligand for transition metal catalysts in various cross-coupling reactions.
|
|---|---|
| ln Vitro |
High-voltage batteries contain an additive called tris(pentafluorophenyl)phosphine. It serves as a derivatization reagent, coupling reagent, and building block.
Specific in vitro activity data for Tris(pentafluorophenyl)phosphine as a pharmacological agent are not documented in the literature, as it is primarily used as a chemical reagent and ligand in organometallic chemistry. The compound is not characterized for direct biological activities such as enzyme inhibition, receptor modulation, or antimicrobial effects. Its effects in biological systems, if any, would be related to its potential toxicity as an organophosphorus compound. |
| ln Vivo |
Tris(pentafluorophenyl)phosphine is not used for in vivo pharmacological activity assessment as a drug compound. Its primary applications are as a chemical reagent and ligand in catalysis research. The compound is not intended to be administered to animals for pharmacological or toxicological studies. Its use is limited to chemical synthesis in laboratory settings.
|
| Enzyme Assay |
It is not used in enzyme/receptor binding assays. Its primary applications are as a ligand in cross-coupling reactions. When used in research, it serves as a ligand for palladium-catalyzed reactions. Standard synthetic chemistry protocols are employed for its use, rather than biochemical assay procedures.
|
| Cell Assay |
It is not used in cell-based assays as a test compound. Its primary applications are as a chemical reagent and ligand in organic synthesis. The compound is not characterized for direct cellular effects. Its potential toxicity is a concern in laboratory settings, but it is not evaluated for pharmacological effects.
|
| Animal Protocol |
It is not used in animal studies as a pharmacological agent. Its primary applications are as a chemical reagent and ligand in catalysis research. The compound is not intended to be administered to animals for efficacy evaluations. Its use is limited to chemical synthesis in laboratory settings.
|
| ADME/Pharmacokinetics |
It has a molecular weight of 532.13 g/mol and a molecular formula of C₁₈F₁₅P. It is a white to pale yellow crystalline solid. It is used as a ligand in organometallic chemistry and catalysis. It is typically stored under standard laboratory conditions, protected from air and moisture.
|
| Toxicity/Toxicokinetics |
It is intended for research use only and is not approved for human therapeutic applications. As an organophosphorus compound, it may be toxic and should be handled with care. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. It should be handled in well-ventilated areas with proper waste disposal procedures.
|
| Additional Infomation |
It is not a drug and is a chemical reagent.
|
| Molecular Formula |
C18F15P
|
|---|---|
| Molecular Weight |
532.15
|
| Exact Mass |
531.949
|
| CAS # |
1259-35-4
|
| PubChem CID |
102076
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
343.4±42.0 °C at 760 mmHg
|
| Melting Point |
108-110 °C(lit.)
|
| Flash Point |
161.5±27.9 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| LogP |
6.24
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
34
|
| Complexity |
566
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(=C(C(=C(C(=C1F)F)P(C2=C(C(=C(C(=C2F)F)F)F)F)C3=C(C(=C(C(=C3F)F)F)F)F)F)F)F
|
| InChi Key |
FQLSDFNKTNBQLC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18F15P/c19-1-4(22)10(28)16(11(29)5(1)23)34(17-12(30)6(24)2(20)7(25)13(17)31)18-14(32)8(26)3(21)9(27)15(18)33
|
| Chemical Name |
tris(2,3,4,5,6-pentafluorophenyl)phosphane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8792 mL | 9.3958 mL | 18.7917 mL | |
| 5 mM | 0.3758 mL | 1.8792 mL | 3.7583 mL | |
| 10 mM | 0.1879 mL | 0.9396 mL | 1.8792 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
